Diabetes

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

https://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/

Lilly surges on positive phase 3 readout from diabetes contender

https://pharmaphorum.com/news/lilly-surges-on-positive-phase-3-readout-from-diabetes-contender/

https://pharmaphorum.com/partner-content/first-results-of-the-diabetrisk-study/

Helixmith starts new trial of diabetic neuropathy gene therapy

https://pharmaphorum.com/r-d/helixmith-starts-new-trial-of-diabetic-neuropathy-gene-therapy/

Towards a new understanding of cardiovascular risk in diabetes

https://pharmaphorum.com/r-d/views-analysis-r-d/towards-a-new-understanding-of-cardiovascular-risk-in-diabetes/

Pharma’s response to COVID-19: Lilly and diabetes care

https://pharmaphorum.com/r-d/views-analysis-r-d/pharmas-response-to-covid-lilly-and-diabetes-care/

Novo Nordisk to buy Emisphere and diabetes pill tech for $1.8bn

https://pharmaphorum.com/news/novo-nordisk-to-buy-emisphere-and-diabetes-pill-tech-for-1-8bn/

Sensyne Health launches diabetes app in the UK

https://pharmaphorum.com/news/sensyne-health-launches-diabetes-app-in-the-uk/

Novo Nordisk beats Q2 profit forecasts by cutting costs

https://pharmaphorum.com/news/novo-nordisk-beats-q2-profit-forecasts-by-cutting-costs/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search